COMMUNIQUÉS West-GlobeNewswire

Avivagen Announces Large Order for OxC-beta™ Livestock and Expansion into Additional Applications
28/02/2019
OTTAWA, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that its partner in the Philippines, UNAHCO, has purchased 2 metric tons of OxC-beta™ Livestock, and follows an [...]
AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
28/02/2019
Reported positive top-line data from an interim analysis of a Phase 2a proof-of-concept trial of etokimab in severe eosinophilic asthma Four top-line Phase 2 clinical efficacy readouts from our wholly-owned pipeline [...]
Terveystalo has become a shareholder of a new pharmacy chain company – The new Olo-apteekki pharmacy develops health services
28/02/2019
Press release, 28 February 2019 Terveystalo has become a shareholder of the new joint venture pharmacy chain company established together by Tamro and independent pharmacists. This chain is called “Olo-apteekki”, and it [...]
Capital Senior Living Corporation Reports Fourth Quarter and Full Year 2018 Results; Announces Changes to Senior Leadership
28/02/2019
Michael C. Fryar Appointed Chief Revenue Officer DALLAS, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (the “Company”) (NYSE: CSU), one of the nation’s largest operators of senior housing [...]
Abstract from AroCell accepted for poster presentation during AACR 2019
28/02/2019
An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study compares AroCell TK210 [...]
Notice of Annual General Meeting
28/02/2019
Valby, Denmark, 28 February 2019 – Notice is hereby given of the Annual General Meeting of H. Lundbeck A/S to be held on: Tuesday 26 March 2019 at 10:00 am The general meeting will be held at the offices of the Company [...]
LIDDS Bokslutskommuniké 2018
28/02/2019
OKTOBER - DECEMBER 2018 Nettoomsättningen uppgick till 0,0 (0,4) KSEK Kostnaderna uppgick till 5,0 (2,6) MSEK Resultatet före och efter skatt uppgick till -4,9 (-2,2) MSEK Resultat per aktie uppgick till -0,21 (-0,11) [...]
Biocartis Group NV: Biocartis announces CE-IVD marking of its Idylla(TM) MSI Test
28/02/2019
PRESS RELEASE 28 February 2019, 07:01 CET Biocartis announces CE-IVD marking of its Idylla(TM) MSI Test Mechelen, Belgium, 28 February 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2018
28/02/2019
Financial Statements Release January 1-December 31, 2018 Progress from safety studies toward clinical proof-of-concept Highlights in January-December 2018: Herantis Pharma ("Herantis") completed the patient enrolment in [...]
Financière de Tubize SA : Annual Financial Report 2018
28/02/2019
Press release 28 February 2019 - 8:00h CET FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Annual financial report 2018 Regulated [...]
Financière de Tubize SA : Rapport financier annuel 2018
28/02/2019
Communiqué de presse 28 février 2019 - 8:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Rapport financier annuel 2018 Information [...]
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
28/02/2019
Leuven, Belgium, 28 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it [...]
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
28/02/2019
LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
EUROBIO SCIENTIFIC : SUCCES D'UNE AUGMENTATION DE CAPITAL PAR PLACEMENT PRIVE DE 3 MILLIONS D’EUROS
28/02/2019
EUROBIO SCIENTIFIC ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL PAR VOIE DE PLACEMENT PRIVE POUR UN MONTANT DE 3 MILLIONS D’EUROS Emission de 1 million d’actions ordinaires nouvelles avec suppression du droit [...]
Terveystalo Plc: Report by the Board of Directors, Financial Statements and Corporate Governance Statement 2018 published
28/02/2019
Terveystalo Plc Annual Financial Report 28 February at 9:00 am EET Terveystalo has published its Annual Report 2018 at https://www.terveystalo.com/en/annual-review-2018/ . The Annual Report 2018 includes the Report by [...]
Genmab A/S Summons Annual General Meeting
28/02/2019
Company Announcement Genmab A/S to hold Annual General Meeting on March 29, 2019 Copenhagen, Denmark; Thursday, February 28, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General Meeting on Friday, March [...]
MDxHealth (R): MDxHealth Reports Financial Year 2018 Results and Provides Outlook for 2019
28/02/2019
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, February 28, 2019 - MDxHealth SA (Euronext: MDXH.BR), today announced its business update and financial results for the year ended [...]
MDxHealth (R) : MDxHealth communique ses résultats financiers pour l'exercice 2018 et ses perspectives pour 2019
28/02/2019
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, jeudi 28 février 2019 - MDxHealth SA (Euronext : MDXH.BR) publie aujourd'hui son rapport d'activité et ses résultats [...]
Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
28/02/2019
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an [...]

Pages